References
- Lonser R, Glenn G, Walther M, et al. Von Hippel – Lindau disease. Lancet 2003; 361: 2059–2067
- Maher E, Iselius L, Yates J, et al. Von Hippel – Lindau disease: a genetic study. J Med Genet 2000; 37: 62–63
- Wanebo J, Lonser R, Glenn G, Oldfield E. The natural history of haemangioblastomas of the central nervous system in patients with von Hippel – Lindau disease. J Neurosurgery 2003; 98: 82–84
- Glasker S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Familial Cancer 2005; 4: 37–42
- Shuin T, Yamasaki I, Tamura K, et al. Von Hippel – Lindau: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumours and treatment. Jap J Clin Oncol 2006; 36(6)337–343
- Ertas G, Altungdag M, Ucer A, Cankat F, Altungdag K. Treatment of recurrent cerebellar haemangioblastoma with external radiotherapy in a patient with von Hippel – Lindau disease: a case report and review of the literature. J Neuro-Oncology 2005; 73: 273–275
- Piribauer M, Czech T, Dieckmann K, et al. Stabilisation of progressive haemangioblastoma under treatment with thalidomide. J Neuro-Oncology 2004; 66: 295–299
- Madhusudan S, Deplanque G, Braybrooke J, Cattell E, Taylor M. Antiangiogenic therapy for von Hippel – Lindau disease. JAMA 2004; 291: 943–944
- Friedrich C. Genotype – phenotype correlation in von Hippel – Lindau syndrome. Hum Mol Gen 2001; 10(7)763–767
- Webster A, Richards F, MacRonald F, Moore A, Maher E. An analysis of phenotypic variation in the familial cancer syndrome von Hippel – Lindau disease: evidence for modifier effects. Am J Hum Genet 1998; 63: 1025–1035